Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ortho-hydroxybenzoic acid or derivative doai
Reexamination Certificate
2006-02-02
2009-12-29
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ortho-hydroxybenzoic acid or derivative doai
C514S160000, C514S161000, C514S162000, C514S163000, C514S164000, C514S165000, C514S166000, C514S474000
Reexamination Certificate
active
07638507
ABSTRACT:
Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.
REFERENCES:
patent: 4496553 (1985-01-01), Halskov
patent: 4904474 (1990-02-01), Theeuwes et al.
patent: 4980173 (1990-12-01), Halskov
patent: 5013727 (1991-05-01), Halskov
patent: 5041431 (1991-08-01), Halskov
patent: 5294630 (1994-03-01), Blake et al.
patent: 5378470 (1995-01-01), Lahr
patent: 5409711 (1995-04-01), Mapelli et al.
patent: 5519014 (1996-05-01), Borody
patent: 5541170 (1996-07-01), Rhodes et al.
patent: 5541171 (1996-07-01), Rhodes et al.
patent: 5552439 (1996-09-01), Panetta
patent: 5604231 (1997-02-01), Smith et al.
patent: 5945411 (1999-08-01), Larson et al.
patent: 5948818 (1999-09-01), Buser et al.
patent: 5973009 (1999-10-01), Tailhan-Lomont et al.
patent: 6004581 (1999-12-01), Jepsen et al.
patent: 6028095 (2000-02-01), Guglietta
patent: 6258852 (2001-07-01), Flitter et al.
patent: 6271265 (2001-08-01), Flitter et al.
patent: 6277836 (2001-08-01), Borody
patent: 6387952 (2002-05-01), Mazurek et al.
patent: 6413494 (2002-07-01), Lee et al.
patent: 6444221 (2002-09-01), Shapiro
patent: 6551620 (2003-04-01), Otterbeck
patent: 6632454 (2003-10-01), Beckert et al.
patent: 6689788 (2004-02-01), Bergeron, Jr.
patent: 6699894 (2004-03-01), Earle et al.
patent: 6717012 (2004-04-01), Wang et al.
patent: 6730702 (2004-05-01), Kono et al.
patent: 6773720 (2004-08-01), Villa et al.
patent: 6797729 (2004-09-01), Byrne et al.
patent: WO 95/31194 (1995-11-01), None
patent: PCT/US2005/009269 (2005-08-01), None
Konstantions, A., et al. “Current theories on the causes of inflammatory bowel disease.”Gastroenterology Clinics of North America, vol. 28, No. 2: pp. 283-296; Jun. 1999.
Sands, B.E., “Novel therapies for inflammatory bowel disease.”Gastroenterology Clinics of North America, vol. 28, No. 2: pp. 323-351; Jun. 1999.
Sands, B.E., “Crohn's Disease. In: Gastrointestinal and Liver Disease.” Eds. M Feldman, LS Friedman, MH Sleisenger. Saunders; New York, 7thEdition: pp. 2005-2038; 2002.
Grisham, M.B., “Oxidants and free radicals in inflammatory bowel disease.”Lancet, vol. 344: pp. 859-861' Sep. 1994.
Krieglstein, C.F., et al., “Regulation of murine intestinal inflammation by reactive metabolites of oxygen and nitrogen: Divergent roles of superoxide and nitric oxide.”J Exp Med, vol. 194, No. 9: pp. 1207-1218; Nov. 2001.
Rachmilewitz, D., et al. “Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity.”Gut, vol. 37: pp. 247-255; 1995.
McCafferty, D.M., et al., “Role of inducible nitric oxide synthase in Trinitrobenzene sulphonic acid induced colitis in mice.”Gut, vol. 45: pp. 864-873; 1999.
Ardite, E., et al., “Replenishment of glutathione levels improves mucosal function in experimental acute colitis.”Laboratory Investigation, vol. 80, No. 5: pp. 735-744; May 2000.
Naito, Y., et al. “α Phenyl-N-tert-Butylnitrone provides protection from dextran sulfate sodium-induced colitis in mice.”Antioxidants and Redox Signaling, vol. 4, No. 1: pp. 195-206; 2002.
Morris, G.P., et al., “Hapten-induced model of chronic inflammation and ulceration in the rat colon.”Gastroenterology, vol. 96: pp. 795-803; 1989.
Wallace, J.I., “Release of platelet-activating factor (PAF) and accelerated healing induced by a PAF antagonist in an animal model of chronic colitis.”Can J Physiol Pharmacol, vol. 66: pp. 422-425; 1988.
Gálvez, J., et al., “The intestinal anti-inflammatory activity of UR-12746S on reactivated experimental colitis is mediated through downregulation of cytokine production.”Inflammatory Bowel Diseases, vol. 9, No. 6: pp. 363-371; Nov. 2003.
Loguercio, C., et al., “Glutathione supplementation improves oxidative damage in experimental colitis.”Dig Liver Dis, vol. 35, No. 9: pp. 635-641; Sep. 2003.
Grisham, M.B., “A radical approach to treating inflammation.”Trends in Pharmacological Sci, vol. 21, Issue 4: pp. 119-120; Apr. 2000.
Bantel, H., et al., “Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis.”Am J Gastroenterol, vol. 95, No. 12: pp. 3452-3457; 2000.
MacDermott, R.P., “Progress in understanding the mechanism of action of 5-aminosalicylicacid.”Am J Gastroenterol, vol. 95, No. 12: pp. 3343-3345; 2000.
Green field, S.M., et al., “Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor α: a novel mechanism of action of sulphasalazine.”Gut, vol. 34: pp. 252-256; 1993.
Keshavarzian, A., et al., “Role of reactive oxygen metabolites in experimental colitis.”Gut, vol. 31: pp. 786-790; 1990.
Miller, M.J., et al., “SOD prevents damage and attenuates eicosanoid release in a rabbit model of necrotizing enterocolitis.”Am J Physiol, vol. 255: pp. G556-G565;1988.
Rachmilewitz, D., et al., “Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity.”Gut, vol. 37: pp. 247-255; 1995.
McCafferty, D.M., et al., “Role of inducible nitric oxide synthase in trinitrobenzene sulphonic acid induced colitis in mice.”Gut, vol. 45: pp. 864-873; 1999.
Zingarelli, B., et al., “Reduced oxidative and nitrosative damage in murine experimental colitis in the absence of inducible nitric oxide synthase.”Gut, vol. 45: pp. 199-209; 1999.
Kubes, P., et al., “Nitric oxide and intestinal inflammation.”Am J Med, vol. 109: pp. 150-158; Aug. 1999.
Svartz, N., “Salazopyrin, a new sulfanilamide preparation.”Acta Med Scand, vol. CX, fasc. VI: pp. 576-599; 1942.
Dick, A. P., et al., “Controlled trial of sulphosalazine in treatment of ulcerative colitis.”Gut, vol. 5: pp. 437-442; 1964.
Das, K. M., et al., “Small bowel absorption of sulphasalazine and its hepatic metabolism in human beings, cats and rats.”Gastroenterology, Vo. 77: pp. 280-284; 1979.
Peppercorn, M.A., et al., “The role of intestinal bacteria in the metabolism of salicylazosulphopyridine.”J Pharmacol Exp Ther, vol. 181, No. 3: pp. 555-562; 1972.
Schroder, H., et al., “Absorption, metabolism and excretion of salicylazosulphopyridine in man.”Clin Pharmocol Ther, vol. 13: pp. 539-552; 1972.
Sharon, P., et al., “Role of prostaglandins in ulcerative colitis: Enhanced production during active disease and inhibition by sulfasalazine.”Gastroenterology, vol. 75: pp. 638-640; 1978.
Stein, R.B., et al., “Medical therapy for inflammatory bowel disease.”Gastroenterol Clin North Am, vol. 28: pp. 297-321; 1999.
Barnes, P.J., et al., “Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory disease.”N Engl J Med, vol. 336, No. 15: pp. 1066-1071; Apr. 1997.
Simmonds et al., “Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies”, Aliment Pharmacol. Ther. 1999, vol. 13, pp. 363-372.
Siddiqui, A. et al., “Antioxidant Therapy with N-Acetylcysteine Plus Mesalamine Accelerates Mucosal Healing in a Rodent Model of Colitis”, Digestive Diseases and Sciences, vol. 51, No. 4 (Apr. 2006), pp. 698-705.
Claytor Renee
Padmanabhan Sreeni
Tahmassebi Sam K.
TechLaw LLP
The Board of Regents of the University of Oklahoma
LandOfFree
Compositions for treatment of inflammatory diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for treatment of inflammatory diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for treatment of inflammatory diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4053455